Eclipsebio

📍 San Diego, United States🗓 Founded 2017👥 40 employees💰 Last funded Sep 2023
Biotechnology Research🌐 eclipsebio.com
Website LinkedIn
Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: - The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform - Multiomic characterization of small molecule and small oligonucleotide targets - Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs - Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Singapore
1
United States
1
Frequently asked questions
Who invested in Eclipsebio?
Eclipsebio has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Eclipsebio last raise funding?
The most recent investment in Eclipsebio recorded on gritt.io was in September 2023.
When was Eclipsebio founded?
Eclipsebio was founded in 2017.
What industry is Eclipsebio in?
Eclipsebio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Eclipsebio based?
Eclipsebio is headquartered in San Diego, United States.